BioToxTech Co

BioToxTech Co Capital Expenditures

The Capital Expenditures (CapEx) of BioToxTech Co (086040.KQ) as of Oct 20, 2026 is -2.23 B KRW. In the previous year, Capital Expenditures (CapEx) was -2.38 B KRW — a change of -6.26% (higher).

Capital Expenditures

-2.23 BKRW

YoY

-6.26%

Last updated:

Capital Expenditures (CapEx) of BioToxTech Co is 2025 -2.23 B KRW. Capital Expenditures (CapEx) of BioToxTech Co was 2024 -2.38 B KRW. It decreases by -6.26% higher compared to the previous year.

The BioToxTech Co Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-2.32 B KRW
Jan 1, 2019
-449.34 M KRW
Jan 1, 2020
-1.37 B KRW
Jan 1, 2021
-7.62 B KRW
Jan 1, 2022
-30.79 B KRW
Jan 1, 2023
-4.88 B KRW
Jan 1, 2024
-2.38 B KRW
Jan 1, 2025
-2.23 B KRW
The BioToxTech Co Capital Expenditures history
YEARCapital ExpendituresYoY
-2.23 BKRW-6.26%
-2.38 BKRW-51.23%
-4.88 BKRW-84.14%
-30.79 BKRW+304.07%
-7.62 BKRW+457.59%
-1.37 BKRW+204.09%
-449.34 MKRW-80.62%
-2.32 BKRW-31.99%
-3.41 BKRW+593.63%
-491.52 MKRW-0.97%
-496.36 MKRW+63.84%
-302.94 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Capital Expenditures (CapEx) of BioToxTech Co is -2.23 B KRW in 2025.

Capital Expenditures (CapEx) of BioToxTech Co changed from -2.38 B KRW to -2.23 B KRW, representing a -6.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s BioToxTech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BioToxTech Co

All Key Metrics — BioToxTech Co